Aspirin -- just for men?October 18, 2007First it was an apple, now it is an aspirin a day that may keep the doctor away. Aspirin has become standard for heart attack prevention, but research published in the online open access journal BMC Medicine suggests that this may really be a man's drug. Scientists have long puzzled over why the protective effects of aspirin vary so widely between clinical trials. Some trials show no difference between aspirin and placebo, whilst others report that aspirin reduces the risk of a heart attack by more than 50%. This latest study, from The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, highlights the influence of gender on aspirin's protective powers. Investigators examined the results of 23 previously published clinical trials for the effect for aspirin in heart attack prevention, involving more than 113,000 patients. The authors then analysed how much the ratio of men to women in these trials affected the trials' outcomes. "Trials that recruited predominantly men demonstrated the largest risk reduction in non-fatal heart attacks," says Dr Don Sin, one of the study's authors. "The trials that contained predominately women failed to demonstrate a significant risk reduction in these non-fatal events. We found that a lot of the variability in these trials seems to be due to the gender ratios, supporting the theory that women may be less responsive to aspirin than men for heart protection." The mechanisms of this resistance are not yet understood, although recent studies have shown that men and women have major differences in the structure and physiology of the heart's blood vessels. "From our findings we would caution clinicians on the prescribing aspirin to women, especially for primary prevention of heart attacks," says Dr Sin. "Whether or not other pharmaceutical products would be more effective for women is unclear; more sex-specific studies should now be conducted." BioMed Central |
|||||||||||||||||||||
| Related Aspirin Current Events and Aspirin News Articles Early end to key study on benefits of niacin, a B vitamin, in keeping arteries open was premature Heart experts at Johns Hopkins are calling premature the early halt of a study by researchers at Walter Reed Army Medical Center and Washington Hospital Center on the benefits of combining extended-release niacin, a B vitamin, with cholesterol-lowering statin medications to prevent blood vessel narrowing. Common Pain Relievers May Dilute Power of Flu Shots With flu vaccination season in full swing, research from the University of Rochester Medical Center cautions that use of many common pain killers - Advil, Tylenol, aspirin - at the time of injection may blunt the effect of the shot and have a negative effect on the immune system. News brief: Effects of aspirin and folic acid on inflammation markers for colorectal adenomas Unexpectedly, inflammation markers do not appear to be involved with the chemopreventative effect of aspirin on colorectal adenomas, according to a brief communication published online October 12 in the Journal of the National Cancer Institute. Aspirin Misuse May Have Made 1918 Flu Pandemic Worse The devastation of the 1918-1919 influenza pandemic is well known, but a new article suggests a surprising factor in the high death toll: the misuse of aspirin. Cogent trial shows lack of adverse interaction between clopidogrel and stomach medicine Results from a late breaking clinical trial called COGENT demonstrate that the combination of giving patients clopidogrel, a blood thinner commonly prescribed to patients with cardiovascular disease, and stomach medicines such as omeprazole, known as proton pump inhibitors (PPIs), did not lead to adverse events, as some prior studies had suggested. Aspirin works for primary prevention in moderate and high risk diabetics The beneficial effects of aspirin in primary prevention of cardiovascular events i.e. stroke, MI and cardiac death are known and generally accepted. New strategies for reperfusion therapy A new trial has begun in order to ascertain once and for all whether the best strategy for patients who cannot receive P-PCI is early fibrinolysis, together with mandated angiography. Small peptide found to stop lung cancer tumor growth in mice In new animal research done by investigators at Wake Forest University School of Medicine, scientists have discovered a treatment effective in mice at blocking the growth and shrinking the size of lung cancer tumors, one of the leading causes of cancer death in the world. Genetic variation associated with poorer response, cardiovascular outcomes with use of clopidogrel Patients with a certain genetic variation who received the antiplatelet drug clopidogrel had a decreased platelet response to treatment and among those who had percutaneous coronary intervention (procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries) had an increased risk of having a cardiovascular event in the following year than patients who did not have this variant, according to a study in the August 26 issue of JAMA. Study reveals mounting evidence of fish oil's heart health benefits There is mounting evidence that omega-3 fatty acids from fish or fish oil supplements not only help prevent cardiovascular diseases in healthy individuals, but also reduce the incidence of cardiac events and mortality in patients with existing heart disease. More Aspirin Current Events and Aspirin News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||